ES2587381T3 - Uso de sapacitabina para tratar una enfermedad proliferativa - Google Patents

Uso de sapacitabina para tratar una enfermedad proliferativa Download PDF

Info

Publication number
ES2587381T3
ES2587381T3 ES08737080.5T ES08737080T ES2587381T3 ES 2587381 T3 ES2587381 T3 ES 2587381T3 ES 08737080 T ES08737080 T ES 08737080T ES 2587381 T3 ES2587381 T3 ES 2587381T3
Authority
ES
Spain
Prior art keywords
sapacitabine
treatment cycle
cndac
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08737080.5T
Other languages
English (en)
Spanish (es)
Inventor
Judy Chiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0708021A external-priority patent/GB0708021D0/en
Priority claimed from GB0723723A external-priority patent/GB0723723D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ES2587381T3 publication Critical patent/ES2587381T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES08737080.5T 2007-04-25 2008-04-24 Uso de sapacitabina para tratar una enfermedad proliferativa Active ES2587381T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0708021A GB0708021D0 (en) 2007-04-25 2007-04-25 Use
GB0708021 2007-04-25
GB0723723 2007-12-04
GB0723723A GB0723723D0 (en) 2007-12-04 2007-12-04 Use
PCT/GB2008/001424 WO2008132443A1 (en) 2007-04-25 2008-04-24 Use of sapacitabine to treat proliferative disease

Publications (1)

Publication Number Publication Date
ES2587381T3 true ES2587381T3 (es) 2016-10-24

Family

ID=39719125

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08737080.5T Active ES2587381T3 (es) 2007-04-25 2008-04-24 Uso de sapacitabina para tratar una enfermedad proliferativa

Country Status (6)

Country Link
US (2) US8536188B2 (show.php)
EP (1) EP2148676B1 (show.php)
JP (2) JP5852309B2 (show.php)
ES (1) ES2587381T3 (show.php)
PL (1) PL2148676T3 (show.php)
WO (1) WO2008132443A1 (show.php)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
EP2874631A1 (en) * 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
LT2941233T (lt) * 2013-01-07 2020-10-26 The Trustees Of The University Of Pennsylvania Odos t-ląstelių limfomos gydymo kompozicija ir būdas
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478223C (en) * 2002-03-08 2012-05-15 Novartis Ag Combinations comprising epothilone derivatives and alkylating agents
US20050014716A1 (en) * 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
EP1849470B2 (en) * 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
CA2617623A1 (en) * 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa

Also Published As

Publication number Publication date
US9675631B2 (en) 2017-06-13
WO2008132443A1 (en) 2008-11-06
EP2148676B1 (en) 2016-05-25
PL2148676T3 (pl) 2016-12-30
EP2148676A1 (en) 2010-02-03
US8536188B2 (en) 2013-09-17
US20140142058A1 (en) 2014-05-22
US20100125084A1 (en) 2010-05-20
JP5892565B2 (ja) 2016-03-23
JP5852309B2 (ja) 2016-02-03
JP2010525042A (ja) 2010-07-22
JP2015013877A (ja) 2015-01-22

Similar Documents

Publication Publication Date Title
ES2587381T3 (es) Uso de sapacitabina para tratar una enfermedad proliferativa
ES3009733T3 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN105517548B (zh) 用于治疗过度增生性病症的mek抑制剂和erk抑制剂的组合
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
ES2672106T3 (es) Suspensiones de derivados de nucleósidos pirimidínicos cristalinos en cápsulas
US20250304612A1 (en) Therapeutic agent for blood cancer
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
JP7032406B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
JP2004517961A (ja) 癌治療法
US8124593B2 (en) Methods of treatment using sapacitabine
PT2754441E (pt) Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina
ES2215307T3 (es) Composiciones con accion sinergica para combatir selectivamente tejidos tumorales.
CN104706656B (zh) 一种用于防治痴呆的天麻提取物或组合物
ES2249616T3 (es) Citidina-fosfocolina para el tratamiento de la neuropatia diabetica.
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
CN100358533C (zh) 用于药物诱导的神经病的药物组合物
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
JP7447013B2 (ja) １，２－ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物
ES2299725T3 (es) Empleo de los derivados anfifilos del acido nucleosido fosfonoformico para el tratamiento de enfermedades infecciosas viricas.
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
CN104619325A (zh) 治疗肿瘤的组合药物及其应用
BR112019022459B1 (pt) Ácido nucleico modificado por oligonucleotídeo
ES2594499A1 (es) Complejos de Rutenio para el tratamiento del cáncer